文献速递焦虑、强迫与应激相关障碍

前额叶不同亚区介导的焦虑对西酞普兰与氯胺酮敏感性不同

Heightened Anxiety With Distinct Prefrontal Substrates Is Differentially Sensitive to the Anxiolytics Citalopram and Ketamine.
PubMed 文献 · Biol Psychiatry · 2025-06-25

该研究在狨猴不确定威胁范式下,分别通过过激活vmPFC-14或失活OFC-11诱导两种病理性焦虑状态,比较SSRI西酞普兰与氯胺酮的疗效。结果发现vmPFC-14过激活所致焦虑对西酞普兰敏感,而OFC-11失活所致焦虑仅对中枢氯胺酮敏感,提示不同前额叶功能异常所致焦虑对药物反应存在差异。

要点

  • vmPFC-14过激活诱导的威胁反应增高可被西酞普兰外周或中枢给药改善。
  • OFC-11失活诱导的威胁反应增高仅对中枢氯胺酮预处理敏感,对SSRI不敏感。
  • 不同前额叶功能异常所致焦虑对同类抗焦虑药反应不同,支持焦虑异质性。

核心结论

  • 不同形式的前额叶功能失调所产生的焦虑状态对西酞普兰和氯胺酮的反应存在差异。

研究设计与样本

  • 在狨猴不确定威胁范式(人类入侵者测试)中,对两个队列(N=14)分别向vmPFC-14或OFC-11置管。
  • 通过阻断谷氨酸再摄取过激活vmPFC-14,或经GABA激动剂输注失活OFC-11,诱导威胁反应增高。
  • 比较西酞普兰和氯胺酮经外周和中枢给药对威胁反应增高的改善效果。

主要发现

  • vmPFC-14过激活诱导的威胁反应增高对西酞普兰外周和中枢给药均有反应。
  • vmPFC-14过激活诱导的威胁反应增高在氯胺酮外周或中枢亚急性预处理下改善不一致。
  • OFC-11失活诱导的威胁反应增高对中枢氯胺酮预处理有反应,但对SSRI外周或中枢给药无反应。

临床怎么用

  • 提示临床焦虑患者的前额叶功能异常类型可能影响其对SSRI或氯胺酮的治疗反应,支持按神经病因分层选药。

局限性

  • 研究为狨猴动物实验,样本量N=14,结论向人类临床外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Individual variability in pharmacological treatment efficacy remains a persistent obstacle to ameliorating clinical anxiety. This may originate, in part, from the different neural etiologies that underlie pathological anxiety. To provide novel insights into patient heterogeneity in anxiolytic responsiveness, we compared the efficacy of distinct anxiolytic drugs, a selective serotonin reuptake inhibitor (SSRI) and ketamine, on anxiety states with different etiologies, but of known origin, in marmoset monkeys. METHODS: Using an uncertain threat paradigm, the human intruder test, we cannulated 2 cohorts of marmosets (Callithrix jacchus) (N = 14) in either area 14 of the ventromedial prefrontal cortex (vmPFC-14) or area 11 of the orbitofrontal cortex (OFC-11). This allowed for induction of heightened threat reactivity by either overactivation of vmPFC-14 by blocking glutamate reuptake or inactivation of OFC-11 by infusion of GABA (gamma-aminobutyric acid) agonists. The efficacy of the SSRI citalopram and ketamine administered both peripherally and centrally to ameliorate the heightened threat reactivity were then compared. RESULTS: Heightened threat reactivity induced by vmPFC-14 overactivation was responsive to citalopram administered both peripherally and centrally into vmPFC-14. However, it was inconsistently reduced by subacute ketamine pretreatment administered either peripherally or centrally. In contrast, heightened threat reactivity induced by inactivation of OFC-11 was responsive to centrally applied pretreatment of ketamine but not peripheral or central SSRI administration. CONCLUSIONS: These data provide evidence that different faces of anxiety generated by distinct forms of prefrontal dysregulation are differentially responsive to differing classes of anxiolytics, providing novel insight into the relationship between the neuro-etiology of anxiety and its treatment.

来源:Biol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Mulvihill KG, Cockcroft GJ, Roberts AC, et al. Heightened Anxiety With Distinct Prefrontal Substrates Is Differentially Sensitive to the Anxiolytics Citalopram and Ketamine. Biol Psychiatry. 2025. PMID: 40578732. doi:10.1016/j.biopsych.2025.06.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。